Literature DB >> 35083661

Quantitative Phosphoproteomics Reveals Extensive Protein Phosphorylation Dysregulation in the Cerebral Cortex of Huntington's Disease Mice Prior to Onset of Symptoms.

Isaline Mees1, Harvey Tran1, Anne Roberts1,2, Larissa Lago1, Shanshan Li1, Blaine R Roberts1,2, Anthony J Hannan1,3, Thibault Renoir4,5.   

Abstract

Protein phosphorylation plays a role in many important cellular functions such as cellular plasticity, gene expression, and intracellular trafficking. All of these are dysregulated in Huntington's disease (HD), a devastating neurodegenerative disorder caused by an expanded CAG repeat in exon 1 of the huntingtin gene. However, no studies have yet found protein phosphorylation differences in preclinical HD mouse models. Our current study investigated changes occurring in the cortical phosphoproteome of 8-week-old (prior to motor deficits) and 20-week-old (fully symptomatic) R6/1 transgenic HD mice. When comparing 8-week-old HD mice with their wild-type (WT) littermates, we found 660 peptides differentially phosphorylated, which were mapped to 227 phosphoproteins. These proteins were mainly involved in synaptogenesis, cytoskeleton organization, axon development, and nervous system development. Tau protein, found hyperphosphorylated at multiple sites in early symptomatic HD mice, also appeared as a main upstream regulator for the changes observed. Surprisingly, we found fewer changes in the phosphorylation profile of HD mice at the fully symptomatic stage, with 29 peptides differentially phosphorylated compared to WT mice, mapped to 25 phosphoproteins. These proteins were involved in cAMP signaling, dendrite development, and microtubule binding. Furthermore, huntingtin protein appeared as an upstream regulator for the changes observed at the fully symptomatic stage, suggesting impacts on kinases and phosphatases that extend beyond the mutated polyglutamine tract. In summary, our findings show that the most extensive changes in the phosphorylation machinery appear at an early presymptomatic stage in HD pathogenesis and might constitute a new target for the development of treatments.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Huntington’s disease; Phosphoproteomics; R6/1 HD mice; Tau

Mesh:

Substances:

Year:  2022        PMID: 35083661     DOI: 10.1007/s12035-021-02698-y

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  54 in total

Review 1.  Phosphoproteomics of Alzheimer disease brain: Insights into altered brain protein regulation of critical neuronal functions and their contributions to subsequent cognitive loss.

Authors:  D Allan Butterfield
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-08-29       Impact factor: 5.187

2.  Mutant huntingtin alters Tau phosphorylation and subcellular distribution.

Authors:  David Blum; Federico Herrera; Laetitia Francelle; Tiago Mendes; Marie Basquin; Hélène Obriot; Dominique Demeyer; Nicolas Sergeant; Ellen Gerhardt; Emmanuel Brouillet; Luc Buée; Tiago F Outeiro
Journal:  Hum Mol Genet       Date:  2014-08-20       Impact factor: 6.150

Review 3.  Integrating phosphoproteomics into kinase-targeted cancer therapies in precision medicine.

Authors:  Xiaomo Wu; Xiaohua Xing; Djameel Dowlut; Yongyi Zeng; Jingfeng Liu; Xiaolong Liu
Journal:  J Proteomics       Date:  2018-04-03       Impact factor: 4.044

4.  Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice.

Authors:  L Mangiarini; K Sathasivam; M Seller; B Cozens; A Harper; C Hetherington; M Lawton; Y Trottier; H Lehrach; S W Davies; G P Bates
Journal:  Cell       Date:  1996-11-01       Impact factor: 41.582

Review 5.  Protein kinases and phosphatases: the yin and yang of protein phosphorylation and signaling.

Authors:  T Hunter
Journal:  Cell       Date:  1995-01-27       Impact factor: 41.582

6.  Differential effects of voluntary physical exercise on behavioral and brain-derived neurotrophic factor expression deficits in Huntington's disease transgenic mice.

Authors:  T Y C Pang; N C Stam; J Nithianantharajah; M L Howard; A J Hannan
Journal:  Neuroscience       Date:  2006-05-22       Impact factor: 3.590

7.  Phosphodiesterase 10A Inhibition Improves Cortico-Basal Ganglia Function in Huntington's Disease Models.

Authors:  Vahri Beaumont; Sheng Zhong; Hai Lin; WenJin Xu; Amyaouch Bradaia; Esther Steidl; Melanie Gleyzes; Kristian Wadel; Bruno Buisson; Fernando E Padovan-Neto; Shreaya Chakroborty; Karen M Ward; John F Harms; Jose Beltran; Mei Kwan; Afshin Ghavami; Jenny Häggkvist; Miklós Tóth; Christer Halldin; Andrea Varrone; Christoph Schaab; J Nikolaj Dybowski; Sarah Elschenbroich; Kimmo Lehtimäki; Taneli Heikkinen; Larry Park; James Rosinski; Ladislav Mrzljak; Daniel Lavery; Anthony R West; Christopher J Schmidt; Margaret M Zaleska; Ignacio Munoz-Sanjuan
Journal:  Neuron       Date:  2016-12-01       Impact factor: 17.173

8.  Gene-environment interactions modulating cognitive function and molecular correlates of synaptic plasticity in Huntington's disease transgenic mice.

Authors:  Jess Nithianantharajah; Christopher Barkus; Mark Murphy; Anthony J Hannan
Journal:  Neurobiol Dis       Date:  2007-11-24       Impact factor: 5.996

9.  Short-term memory acquisition in female Huntington's disease mice is vulnerable to acute stress.

Authors:  Christina Mo; Thibault Renoir; Terence Y C Pang; Anthony J Hannan
Journal:  Behav Brain Res       Date:  2013-07-31       Impact factor: 3.332

10.  N-Acetylcysteine improves mitochondrial function and ameliorates behavioral deficits in the R6/1 mouse model of Huntington's disease.

Authors:  D J Wright; T Renoir; Z M Smith; A E Frazier; P S Francis; D R Thorburn; S L McGee; A J Hannan; L J Gray
Journal:  Transl Psychiatry       Date:  2015-01-06       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.